Summary
A 57-year-old senior cyber and software expert was granted a security clearance under Guideline H (Drug Involvement) despite initial concerns. The Statement of Reasons alleged a history of marijuana use, including after submitting his Security Clearance Application (SCA), and an expressed intent to continue use. These allegations raised Disqualifying Conditions AG ¶ 25(a), AG ¶ 25(c), and AG ¶ 25(g).
However, the judge applied Mitigating Conditions AG ¶ 26(a) and AG ¶ 26(b). The applicant successfully demonstrated a commitment to abstain from marijuana, having not used it for over a year. He also showed a clear understanding of the implications of drug use on security clearance eligibility and expressed a firm intent to refrain from future use.
The judge found the applicant's testimony credible, noting his professional responsibility and good judgment. Based on this demonstrated commitment and sustained abstinence, the security clearance was granted.
Why the Applicant Prevailed
- The applicant has abstained from marijuana use for over a year.
- He demonstrated a clear commitment to refrain from future marijuana use.
- The judge found the applicant's testimony credible and noted his professional responsibility.
Conditions Referenced
- AG ¶ 25(a)raisedSubstance Misuse
- AG ¶ 25(c)raisedIllegal Possession of a Controlled Substance
- AG ¶ 25(g)rejectedIntent to Continue Drug InvolvementThe applicant has clearly and convincingly committed to abstain from future marijuana use.
- AG ¶ 26(a)appliedBehavior Unlikely to Recur
- AG ¶ 26(b)appliedAcknowledgment of Drug Involvement and Pattern of Abstinence
Key Rule Quoted
“The protection of the national security is the paramount consideration.”
Procedural Posture
- SOR issuedJul 6, 2021
- Answer filedJul 11, 2021
- Hearing heldMay 20, 2022Hearing was delayed due to COVID-19 pandemic.
- Decision dateAug 4, 2022
Cite For
- Mitigating Conditions for Drug Involvement Under Guideline H
- Credibility of Applicant's Testimony Regarding Abstinence
- Commitment to Refrain From Future Drug Use as a Basis for Clearance Approval.